Updates in IDH-Wildtype Glioblastoma

Glioblastoma is the most aggressive primary brain tumor with a poor prognosis. The 2021 WHO CNS5 classification has further stressed the importance of molecular signatures in diagnosis although therapeutic breakthroughs are still lacking. In this review article, updates on the current and novel ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Melhem, Jawad M., Detsky, Jay, Lim-Fat, Mary Jane, Perry, James R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9154038/
https://www.ncbi.nlm.nih.gov/pubmed/35641844
http://dx.doi.org/10.1007/s13311-022-01251-6
_version_ 1784717956820762624
author Melhem, Jawad M.
Detsky, Jay
Lim-Fat, Mary Jane
Perry, James R.
author_facet Melhem, Jawad M.
Detsky, Jay
Lim-Fat, Mary Jane
Perry, James R.
author_sort Melhem, Jawad M.
collection PubMed
description Glioblastoma is the most aggressive primary brain tumor with a poor prognosis. The 2021 WHO CNS5 classification has further stressed the importance of molecular signatures in diagnosis although therapeutic breakthroughs are still lacking. In this review article, updates on the current and novel therapies in IDH-wildtype GBM will be discussed. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13311-022-01251-6.
format Online
Article
Text
id pubmed-9154038
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-91540382022-06-02 Updates in IDH-Wildtype Glioblastoma Melhem, Jawad M. Detsky, Jay Lim-Fat, Mary Jane Perry, James R. Neurotherapeutics Review Glioblastoma is the most aggressive primary brain tumor with a poor prognosis. The 2021 WHO CNS5 classification has further stressed the importance of molecular signatures in diagnosis although therapeutic breakthroughs are still lacking. In this review article, updates on the current and novel therapies in IDH-wildtype GBM will be discussed. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13311-022-01251-6. Springer International Publishing 2022-05-31 2022-10 /pmc/articles/PMC9154038/ /pubmed/35641844 http://dx.doi.org/10.1007/s13311-022-01251-6 Text en © The American Society for Experimental NeuroTherapeutics, Inc. 2022
spellingShingle Review
Melhem, Jawad M.
Detsky, Jay
Lim-Fat, Mary Jane
Perry, James R.
Updates in IDH-Wildtype Glioblastoma
title Updates in IDH-Wildtype Glioblastoma
title_full Updates in IDH-Wildtype Glioblastoma
title_fullStr Updates in IDH-Wildtype Glioblastoma
title_full_unstemmed Updates in IDH-Wildtype Glioblastoma
title_short Updates in IDH-Wildtype Glioblastoma
title_sort updates in idh-wildtype glioblastoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9154038/
https://www.ncbi.nlm.nih.gov/pubmed/35641844
http://dx.doi.org/10.1007/s13311-022-01251-6
work_keys_str_mv AT melhemjawadm updatesinidhwildtypeglioblastoma
AT detskyjay updatesinidhwildtypeglioblastoma
AT limfatmaryjane updatesinidhwildtypeglioblastoma
AT perryjamesr updatesinidhwildtypeglioblastoma

Ejemplares similares